Prices, Costs, and Affordability of New Medicines for Hepatitis C in 30 Countries: An Economic Analysis

Restrictions for Medicaid Reimbursement of Sofosbuvir for the Treatment of Hepatitis C Virus Infection in the United States

(2015) Soumitri Barua et al.   ANNALS OF INTERNAL MEDICINE

Cost-Effectiveness and Budget Impact of Hepatitis C Virus Treatment With Sofosbuvir and Ledipasvir in the United States

(2015) Jagpreet Chhatwal et al.   ANNALS OF INTERNAL MEDICINE

A Budget Impact Analysis of Newly Available Hepatitis C Therapeutics and the Financial Burden on a State Correctional System

(2015) John T. Nguyen et al.   JOURNAL OF URBAN HEALTH-BULLETIN OF THE NEW YORK ACADEMY OF MEDICINE

Global, regional, and national age–sex specific all-cause and cause-specific mortality for 240 causes of death, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013

(2015)   LANCET

In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs

(2015) Ayalew Tefferi et al.   MAYO CLINIC PROCEEDINGS

Mixed HCV infection and reinfection in people who inject drugs—impact on therapy

(2015) Evan B. Cunningham et al.   Nature Reviews Gastroenterology & Hepatology

Access to critical medicines: When are compulsory licenses effective in price negotiations?

(2015) Shyama V. Ramani et al.   SOCIAL SCIENCE & MEDICINE

Disparity in market prices for hepatitis C virus direct-acting drugs

(2015) Isabelle Andrieux-Meyer et al.   Lancet Global Health

Minimum Costs for Producing Hepatitis C Direct-Acting Antivirals for Use in Large-Scale Treatment Access Programs in Developing Countries

(2014) A. Hill et al.   CLINICAL INFECTIOUS DISEASES

Costs of telaprevir-based triple therapy for hepatitis C: $189,000 per sustained virological response

(2014) Kian Bichoupan et al.   HEPATOLOGY

Global epidemiology and genotype distribution of the hepatitis C virus infection

(2014) Erin Gower et al.   JOURNAL OF HEPATOLOGY

Ledipasvir and Sofosbuvir for Previously Treated HCV Genotype 1 Infection

(2014) Nezam Afdhal et al.   NEW ENGLAND JOURNAL OF MEDICINE

Sofosbuvir and Ribavirin in HCV Genotypes 2 and 3

(2014) Stefan Zeuzem et al.   NEW ENGLAND JOURNAL OF MEDICINE

The Comparative Clinical Effectiveness and Value of Simeprevir and Sofosbuvir for Chronic Hepatitis C Virus Infection

(2014) Daniel A. Ollendorf et al.   JAMA Internal Medicine

The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts

(2013)   BLOOD

Mapping the availability, price, and affordability of antiepileptic drugs in 46 countries

(2012) Alexandra Cameron et al.   EPILEPSIA

Allocating scarce financial resources for HIV treatment: benchmarking prices of antiretroviral medicines in Latin America

(2012) Veronika J Wirtz et al.   HEALTH POLICY AND PLANNING

Hepatitis C virus clearance, reinfection, and persistence, with insights from studies of injecting drug users: towards a vaccine

(2012) Jason Grebely et al.   LANCET INFECTIOUS DISEASES

Differences in external price referencing in Europe—A descriptive overview

(2011) Christine Leopold et al.   HEALTH POLICY

Delivering affordable cancer care in high-income countries

(2011) Richard Sullivan et al.   LANCET ONCOLOGY

Driving a decade of change: HIV/AIDS, patents and access to medicines for all

(2011) Ellen 't Hoen et al.   Journal of the International AIDS Society

Evolving epidemiology of hepatitis C virus

(2010) D. Lavanchy   CLINICAL MICROBIOLOGY AND INFECTION

A lifeline to treatment: the role of Indian generic manufacturers in supplying antiretroviral medicines to developing countries

(2010) Brenda Waning et al.   Journal of the International AIDS Society

Effectiveness of hepatitis C treatment with pegylated interferon and ribavirin in urban minority patients

(2009) Paul Feuerstadt et al.   HEPATOLOGY

Medicine prices, availability, and affordability in 36 developing and middle-income countries: a secondary analysis

(2008) A Cameron et al.   LANCET